Just three days after a similar announcement by Pfizer, the American biotech company Moderna announced that its mRNA vaccine against Covid-19 – in lower doses than adults – was well-tolerated and elicited a strong immune response in children ages 6-11.
In the statement, the company cited the results of a randomized, placebo-controlled and blind clinical trial of the KidCOVE vaccine phase 2/3 in 4,753 children, some of whom over time received two doses of the vaccine 28 days apart. Each dose was approximately half (50 micrograms) less than that for adults.
It was found that in children, the production of neutralizing antibodies is about one and a half times higher than in young people who took the full dose. The company said the children experienced some “mild to moderate” side effects, such as fatigue, headaches, fever, and mild pain at the injection site, similar to symptoms found in some adolescents and adults. Children will continue to be monitored for 12 months after the second dose to assess the safety and efficacy of the vaccine over a longer period of time.
A few days ago, Pfizer announced that its proprietary Covid-19 vaccine – also in lower doses – is nearly 91% effective in testing against symptomatic infection in children aged 5-11. The company has already applied for an urgent license for its vaccine for children under 12, which Moderna is only about to do for both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Moderna has already applied to the FDA for approval to administer the vaccine for 12-17 years of age. So far, the FDA has approved Moderna vaccine for people over 18 and Pfizer vaccine for children over 12.
Source: ΑΠΕ – ΜΠΕ